Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-08-04
197000.00 KRW   +4.23%
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50%

06/06/2022 | 03:35am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. 4.23% 197000 End-of-day quote.-0.51%
KOSPI COMPOSITE INDEX 0.80% 2493.1 Real-time Quote.-16.24%
All news about CELLTRION, INC.
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/22Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 sha..
CI
07/19Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle Eas..
AQ
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
MT
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2022 1 969 B 1,51 B 1,51 B
Net income 2022 618 B 0,47 B 0,47 B
Net cash 2022 673 B 0,52 B 0,52 B
P/E ratio 2022 47,1x
Yield 2022 0,17%
Capitalization 27 138 B 20 815 M 20 815 M
EV / Sales 2022 13,4x
EV / Sales 2023 10,7x
Nbr of Employees 2 034
Free-Float 75,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 197 000,00 KRW
Average target price 193 160,78 KRW
Spread / Average Target -1,95%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-0.51%20 815
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235